Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 61

1.

Optimizing ethambutol dosing among HIV/tuberculosis co-infected patients: a population pharmacokinetic modelling and simulation study.

Mehta K, Ravimohan S, Pasipanodya JG, Srivastava S, Modongo C, Zetola NM, Weissman D, Ivaturi V, Gumbo T, Bisson GP, Vinnard C.

J Antimicrob Chemother. 2019 Jul 4. pii: dkz265. doi: 10.1093/jac/dkz265. [Epub ahead of print]

PMID:
31273386
2.

Lung injury on antiretroviral therapy in adults with HIV/TB.

Ravimohan S, Auld SC, Maenetje P, Ratsela N, Mlotshwa M, Ncube I, Smith JP, Vangu MD, Sebe M, Kossenkov A, Weissman D, Wallis RS, Churchyard G, Kornfeld H, Bisson GP.

Clin Infect Dis. 2019 Jun 26. pii: ciz560. doi: 10.1093/cid/ciz560. [Epub ahead of print]

PMID:
31242296
3.

Treatment correlates of successful outcomes in pulmonary multidrug-resistant tuberculosis: an individual patient data meta-analysis.

Collaborative Group for the Meta-Analysis of Individual Patient Data in MDR-TB treatment–2017, Ahmad N, Ahuja SD, Akkerman OW, Alffenaar JC, Anderson LF, Baghaei P, Bang D, Barry PM, Bastos ML, Behera D, Benedetti A, Bisson GP, Boeree MJ, Bonnet M, Brode SK, Brust JCM, Cai Y, Caumes E, Cegielski JP, Centis R, Chan PC, Chan ED, Chang KC, Charles M, Cirule A, Dalcolmo MP, D'Ambrosio L, de Vries G, Dheda K, Esmail A, Flood J, Fox GJ, Fréchet-Jachym M, Fregona G, Gayoso R, Gegia M, Gler MT, Gu S, Guglielmetti L, Holtz TH, Hughes J, Isaakidis P, Jarlsberg L, Kempker RR, Keshavjee S, Khan FA, Kipiani M, Koenig SP, Koh WJ, Kritski A, Kuksa L, Kvasnovsky CL, Kwak N, Lan Z, Lange C, Laniado-Laborín R, Lee M, Leimane V, Leung CC, Leung EC, Li PZ, Lowenthal P, Maciel EL, Marks SM, Mase S, Mbuagbaw L, Migliori GB, Milanov V, Miller AC, Mitnick CD, Modongo C, Mohr E, Monedero I, Nahid P, Ndjeka N, O'Donnell MR, Padayatchi N, Palmero D, Pape JW, Podewils LJ, Reynolds I, Riekstina V, Robert J, Rodriguez M, Seaworth B, Seung KJ, Schnippel K, Shim TS, Singla R, Smith SE, Sotgiu G, Sukhbaatar G, Tabarsi P, Tiberi S, Trajman A, Trieu L, Udwadia ZF, van der Werf TS, Veziris N, Viiklepp P, Vilbrun SC, Walsh K, Westenhouse J, Yew WW, Yim JJ, Zetola NM, Zignol M, Menzies D.

Lancet. 2018 Sep 8;392(10150):821-834. doi: 10.1016/S0140-6736(18)31644-1. Review.

PMID:
30215381
4.

Impact of Efavirenz Metabolism on Loss to Care in Older HIV+ Africans.

Torgersen J, Bellamy SL, Ratshaa B, Han X, Mosepele M, Zuppa AF, Vujkovic M, Steenhoff AP, Bisson GP, Gross R.

Eur J Drug Metab Pharmacokinet. 2019 Apr;44(2):179-187. doi: 10.1007/s13318-018-0507-5.

PMID:
30168000
5.

Short-course High-dose Liposomal Amphotericin B for Human Immunodeficiency Virus-associated Cryptococcal Meningitis: A Phase 2 Randomized Controlled Trial.

Jarvis JN, Leeme TB, Molefi M, Chofle AA, Bidwell G, Tsholo K, Tlhako N, Mawoko N, Patel RKK, Tenforde MW, Muthoga C, Bisson GP, Kidola J, Changalucha J, Lawrence D, Jaffar S, Hope W, Molloy SLF, Harrison TS.

Clin Infect Dis. 2019 Jan 18;68(3):393-401. doi: 10.1093/cid/ciy515.

6.

Polymorphisms in cytochrome P450 are associated with extensive efavirenz pharmacokinetics and CNS toxicities in an HIV cohort in Botswana.

Vujkovic M, Bellamy SL, Zuppa AF, Gastonguay MR, Moorthy GS, Ratshaa B, Han X, Steenhoff AP, Mosepele M, Strom BL, Bisson GP, Aplenc R, Gross R.

Pharmacogenomics J. 2018 Sep;18(5):678-688. doi: 10.1038/s41397-018-0028-2. Epub 2018 Jun 1.

7.

Common Variation in NLRP3 Is Associated With Early Death and Elevated Inflammasome Biomarkers Among Advanced HIV/TB Co-infected Patients in Botswana.

Ravimohan S, Nfanyana K, Tamuhla N, Tiemessen CT, Weissman D, Bisson GP.

Open Forum Infect Dis. 2018 Apr 11;5(5):ofy075. doi: 10.1093/ofid/ofy075. eCollection 2018 May.

8.

Tuberculosis and lung damage: from epidemiology to pathophysiology.

Ravimohan S, Kornfeld H, Weissman D, Bisson GP.

Eur Respir Rev. 2018 Feb 28;27(147). pii: 170077. doi: 10.1183/16000617.0077-2017. Print 2018 Mar 31. Review.

9.

Hepatotoxicity During Isoniazid Preventive Therapy and Antiretroviral Therapy in People Living With HIV With Severe Immunosuppression: A Secondary Analysis of a Multi-Country Open-Label Randomized Controlled Clinical Trial.

Ngongondo M, Miyahara S, Hughes MD, Sun X, Bisson GP, Gupta A, Kumwenda J, Lavenberg JA, Torres TS, Nyirenda M, Kidonge KK, Hosseinipour MC; AIDS Clinical Trials Group A5274 (REMEMBER) Study Team.

J Acquir Immune Defic Syndr. 2018 May 1;78(1):54-61. doi: 10.1097/QAI.0000000000001641.

10.

Urine colorimetry for therapeutic drug monitoring of pyrazinamide during tuberculosis treatment.

Zentner I, Modongo C, Zetola NM, Pasipanodya JG, Srivastava S, Heysell SK, Mpagama S, Schlect HP, Gumbo T, Bisson GP, Vinnard C.

Int J Infect Dis. 2018 Mar;68:18-23. doi: 10.1016/j.ijid.2017.12.017. Epub 2017 Dec 15.

11.

Pyrazinamide clearance is impaired among HIV/tuberculosis patients with high levels of systemic immune activation.

Vinnard C, Ravimohan S, Tamuhla N, Pasipanodya J, Srivastava S, Modongo C, Zetola NM, Weissman D, Gumbo T, Bisson GP.

PLoS One. 2017 Nov 2;12(11):e0187624. doi: 10.1371/journal.pone.0187624. eCollection 2017.

12.

Risk factors for early mortality on antiretroviral therapy in advanced HIV-infected adults.

Bisson GP, Ramchandani R, Miyahara S, Mngqibisa R, Matoga M, Ngongondo M, Samaneka W, Koech L, Naidoo K, Rassool M, Kirui F, Banda P, Mave V, Kadam D, Leger P, Henestroza G, Manabe YC, Bao J, Kumwenda J, Gupta A, Hosseinipour MC; Adult AIDS Clinical Trials Group A5274 (REMEMBER) Study Team.

AIDS. 2017 Oct 23;31(16):2217-2225. doi: 10.1097/QAD.0000000000001606.

13.

CYP2B6 genotypes and early efavirenz-based HIV treatment outcomes in Botswana.

Gross R, Bellamy SL, Ratshaa B, Han X, Vujkovic M, Aplenc R, Steenhoff AP, Mosepele M, Moorthy G, Zuppa AF, Strom BL, Bisson GP.

AIDS. 2017 Sep 24;31(15):2107-2113. doi: 10.1097/QAD.0000000000001593.

14.

Brief Report: CYP2B6 516G>T Minor Allele Protective of Late Virologic Failure in Efavirenz-Treated HIV-Infected Patients in Botswana.

Vujkovic M, Bellamy SL, Zuppa AF, Gastonguay M, Moorthy GS, Ratshaa BR, Han X, Steenhoff AP, Mosepele M, Strom BL, Aplenc R, Bisson GP, Gross R.

J Acquir Immune Defic Syndr. 2017 Aug 1;75(4):488-491. doi: 10.1097/QAI.0000000000001442.

15.

Markers of gut dysfunction do not explain low rifampicin bioavailability in HIV-associated TB.

Vinnard C, Ravimohan S, Tamuhla N, Pasipanodya J, Srivastava S, Modongo C, Zetola NM, Weissman D, Gumbo T, Bisson GP.

J Antimicrob Chemother. 2017 Jul 1;72(7):2020-2027. doi: 10.1093/jac/dkx111.

16.

Elevated Pre-Antiretroviral Therapy CD39+CD8+ T Cell Frequency Is Associated With Early Mortality in Advanced Human Immunodeficiency Virus/Tuberculosis Co-infection.

Ravimohan S, Tamuhla N, Nfanyana K, Ni H, Steenhoff AP, Gross R, Weissman D, Bisson GP.

Clin Infect Dis. 2017 May 15;64(10):1453-1456. doi: 10.1093/cid/cix155. Erratum in: Clin Infect Dis. 2017 Oct 15;65(8):1431-1433.

17.

Isoniazid clearance is impaired among human immunodeficiency virus/tuberculosis patients with high levels of immune activation.

Vinnard C, Ravimohan S, Tamuhla N, Ivaturi V, Pasipanodya J, Srivastava S, Modongo C, Zetola NM, Weissman D, Gumbo T, Bisson GP.

Br J Clin Pharmacol. 2017 Apr;83(4):801-811. doi: 10.1111/bcp.13172. Epub 2016 Dec 9.

18.

Comparative Effectiveness of Diabetic Oral Medications Among HIV-Infected and HIV-Uninfected Veterans.

Han JH, Gordon K, Womack JA, Gibert CL, Leaf DA, Rimland D, Rodriguez-Barradas MC, Bisson GP.

Diabetes Care. 2017 Feb;40(2):218-225. doi: 10.2337/dc16-0718. Epub 2016 Sep 15.

19.

Effects of sex and alcohol use on antiretroviral therapy outcomes in Botswana: a cohort study.

Gross R, Bellamy SL, Ratshaa B, Han X, Steenhoff AP, Mosepele M, Bisson GP.

Addiction. 2017 Jan;112(1):73-81. doi: 10.1111/add.13538. Epub 2016 Sep 7.

20.

Urine colorimetry to detect Low rifampin exposure during tuberculosis therapy: a proof-of-concept study.

Zentner I, Schlecht HP, Khensouvann L, Tamuhla N, Kutzler M, Ivaturi V, Pasipanodya JG, Gumbo T, Peloquin CA, Bisson GP, Vinnard C.

BMC Infect Dis. 2016 Jun 1;16:242. doi: 10.1186/s12879-016-1576-1.

21.

Empirical tuberculosis therapy versus isoniazid in adult outpatients with advanced HIV initiating antiretroviral therapy (REMEMBER): a multicountry open-label randomised controlled trial.

Hosseinipour MC, Bisson GP, Miyahara S, Sun X, Moses A, Riviere C, Kirui FK, Badal-Faesen S, Lagat D, Nyirenda M, Naidoo K, Hakim J, Mugyenyi P, Henostroza G, Leger PD, Lama JR, Mohapi L, Alave J, Mave V, Veloso VG, Pillay S, Kumarasamy N, Bao J, Hogg E, Jones L, Zolopa A, Kumwenda J, Gupta A; Adult AIDS Clinical Trials Group A5274 (REMEMBER) Study Team.

Lancet. 2016 Mar 19;387(10024):1198-209. doi: 10.1016/S0140-6736(16)00546-8.

22.

Matrix Metalloproteinases in Tuberculosis-Immune Reconstitution Inflammatory Syndrome and Impaired Lung Function Among Advanced HIV/TB Co-infected Patients Initiating Antiretroviral Therapy.

Ravimohan S, Tamuhla N, Kung SJ, Nfanyana K, Steenhoff AP, Gross R, Weissman D, Bisson GP.

EBioMedicine. 2015 Nov 25;3:100-107. doi: 10.1016/j.ebiom.2015.11.040. eCollection 2016 Jan.

23.

CD4 Cell Counts at Antiretroviral Therapy Initiation in Botswana Have Been Increasing.

Okatch H, Bellamy SL, Han X, Ratshaa B, Steenhoff AP, Mosepele M, Bisson GP, Gross R.

Clin Infect Dis. 2016 Mar 1;62(5):669-70. doi: 10.1093/cid/civ965. Epub 2015 Dec 13. No abstract available.

24.

Robust Reconstitution of Tuberculosis-Specific Polyfunctional CD4+ T-Cell Responses and Rising Systemic Interleukin 6 in Paradoxical Tuberculosis-Associated Immune Reconstitution Inflammatory Syndrome.

Ravimohan S, Tamuhla N, Nfanyana K, Steenhoff AP, Letlhogile R, Frank I, MacGregor RR, Gross R, Weissman D, Bisson GP.

Clin Infect Dis. 2016 Mar 15;62(6):795-803. doi: 10.1093/cid/civ978. Epub 2015 Nov 26.

25.

Ocular surface squamous neoplasia among HIV-infected patients in Botswana.

Steele KT, Steenhoff AP, Bisson GP, Nkomazana O.

S Afr Med J. 2015 Apr 7;105(5):379-83. doi: 10.7196/samj.8254.

PMID:
26242668
26.

AMBITION-cm: intermittent high dose AmBisome on a high dose fluconazole backbone for cryptococcal meningitis induction therapy in sub-Saharan Africa: study protocol for a randomized controlled trial.

Molefi M, Chofle AA, Molloy SF, Kalluvya S, Changalucha JM, Cainelli F, Leeme T, Lekwape N, Goldberg DW, Haverkamp M, Bisson GP, Perfect JR, Letang E, Fenner L, Meintjes G, Burton R, Makadzange T, Ndhlovu CE, Hope W, Harrison TS, Jarvis JN.

Trials. 2015 Jun 17;16:276. doi: 10.1186/s13063-015-0799-6.

27.

Persistent high mortality in advanced HIV/TB despite appropriate antiretroviral and antitubercular therapy: an emerging challenge.

Bisson GP, Zetola N, Collman RG.

Curr HIV/AIDS Rep. 2015 Mar;12(1):107-16. doi: 10.1007/s11904-015-0256-x. Review.

28.

Immunological profiling of tuberculosis-associated immune reconstitution inflammatory syndrome and non-immune reconstitution inflammatory syndrome death in HIV-infected adults with pulmonary tuberculosis starting antiretroviral therapy: a prospective observational cohort study.

Ravimohan S, Tamuhla N, Steenhoff AP, Letlhogile R, Nfanyana K, Bellamy SL, MacGregor RR, Gross R, Weissman D, Bisson GP.

Lancet Infect Dis. 2015 Apr;15(4):429-38. doi: 10.1016/S1473-3099(15)70008-3. Epub 2015 Feb 9. Erratum in: Lancet Infect Dis. 2015 May;15(5):505.

29.

Early antiretroviral therapy is protective against epilepsy in children with human immunodeficiency virus infection in botswana.

Bearden D, Steenhoff AP, Dlugos DJ, Kolson D, Mehta P, Kessler S, Lowenthal E, Monokwane B, Anabwani G, Bisson GP.

J Acquir Immune Defic Syndr. 2015 Jun 1;69(2):193-9. doi: 10.1097/QAI.0000000000000563.

30.

Clinical outcomes among persons with pulmonary tuberculosis caused by Mycobacterium tuberculosis isolates with phenotypic heterogeneity in results of drug-susceptibility tests.

Zetola NM, Modongo C, Moonan PK, Ncube R, Matlhagela K, Sepako E, Collman RG, Bisson GP.

J Infect Dis. 2014 Jun 1;209(11):1754-63. doi: 10.1093/infdis/jiu040. Epub 2014 Jan 16.

31.

Tuberculin skin test result and risk of death among persons with active TB.

Auld SC, Click ES, Heilig CM, Miramontes R, Cain KP, Bisson GP, Mac Kenzie WR.

PLoS One. 2013 Nov 11;8(11):e78779. doi: 10.1371/journal.pone.0078779. eCollection 2013.

32.

Association between tuberculin skin test result and clinical presentation of tuberculosis disease.

Auld SC, Click ES, Heilig CM, Miramontes R, Cain KP, Bisson GP, Mac Kenzie WR.

BMC Infect Dis. 2013 Oct 4;13:460. doi: 10.1186/1471-2334-13-460.

33.

Outcomes in HIV-infected adults with tuberculosis at clinics with and without co-located HIV clinics in Botswana.

Schwartz AB, Tamuhla N, Steenhoff AP, Nkakana K, Letlhogile R, Chadborn TR, Kestler M, Zetola NM, Ravimohan S, Bisson GP.

Int J Tuberc Lung Dis. 2013 Oct;17(10):1298-303. doi: 10.5588/ijtld.12.0861.

34.

Early immunologic failure is associated with early mortality among advanced HIV-infected adults initiating antiretroviral therapy with active tuberculosis.

Ravimohan S, Tamuhla N, Steenhoff AP, Letlhogile R, Makutu DK, Nfanyana K, Rantleru T, Tierney A, Nkakana K, Schwartz AB, Gross R, Macgregor RR, Bellamy SL, Frank I, Weissman D, Bisson GP.

J Infect Dis. 2013 Dec 1;208(11):1784-93. doi: 10.1093/infdis/jit368. Epub 2013 Aug 1.

35.

Yield of contact tracing from pediatric tuberculosis index cases in Gaborone, Botswana.

Puryear S, Seropola G, Ho-Foster A, Arscott-Mills T, Mazhani L, Firth J, Goldfarb DM, Ncube R, Bisson GP, Steenhoff AP.

Int J Tuberc Lung Dis. 2013 Aug;17(8):1049-55. doi: 10.5588/ijtld.12.0933.

36.

First Use of Multiple Imputation with the National Tuberculosis Surveillance System.

Vinnard C, Wileyto EP, Bisson GP, Winston CA.

Epidemiol Res Int. 2012 Dec 18;2013. pii: 875234.

37.

Early versus delayed antiretroviral therapy and cerebrospinal fluid fungal clearance in adults with HIV and cryptococcal meningitis.

Bisson GP, Molefi M, Bellamy S, Thakur R, Steenhoff A, Tamuhla N, Rantleru T, Tsimako I, Gluckman S, Ravimohan S, Weissman D, Tebas P.

Clin Infect Dis. 2013 Apr;56(8):1165-73. doi: 10.1093/cid/cit019. Epub 2013 Jan 29. Erratum in: Clin Infect Dis. 2013 Oct;57(7):1067.

PMID:
23362285
38.

Impact of the human immunodeficiency virus on early multidrug-resistant tuberculosis treatment outcomes in Botswana.

Hafkin J, Modongo C, Newcomb C, Lowenthal E, MacGregor RR, Steenhoff AP, Friedman H, Bisson GP.

Int J Tuberc Lung Dis. 2013 Mar;17(3):348-53. doi: 10.5588/ijtld.12.0100. Epub 2013 Jan 14.

39.

Vitamin D status in HIV-infected patients with and without tuberculosis: a pilot study.

Steenhoff AP, Redwood A, Pettifor JM, Hove J, Bisson GP, Mosepele M, Pusoesele P, Thakur R, Kovarik C, Gross R.

J Acquir Immune Defic Syndr. 2012 Oct 1;61(2):e21-3. No abstract available.

40.

Upregulation of the phthiocerol dimycocerosate biosynthetic pathway by rifampin-resistant, rpoB mutant Mycobacterium tuberculosis.

Bisson GP, Mehaffy C, Broeckling C, Prenni J, Rifat D, Lun DS, Burgos M, Weissman D, Karakousis PC, Dobos K.

J Bacteriol. 2012 Dec;194(23):6441-52. doi: 10.1128/JB.01013-12. Epub 2012 Sep 21.

41.

Alcohol use and abuse among patients with multidrug-resistant tuberculosis in Botswana.

Zetola NM, Modongo C, Kip EC, Gross R, Bisson GP, Collman RG.

Int J Tuberc Lung Dis. 2012 Nov;16(11):1529-34. doi: 10.5588/ijtld.12.0026. Epub 2012 Sep 7.

42.

HIV infection and glycemic response to newly initiated diabetic medical therapy.

Han JH, Crane HM, Bellamy SL, Frank I, Cardillo S, Bisson GP; Centers for AIDS Research Network of Integrated Clinical Systems (CNICS).

AIDS. 2012 Oct 23;26(16):2087-95. doi: 10.1097/QAD.0b013e328359a8e5.

43.

Early mortality in adults initiating antiretroviral therapy (ART) in low- and middle-income countries (LMIC): a systematic review and meta-analysis.

Gupta A, Nadkarni G, Yang WT, Chandrasekhar A, Gupte N, Bisson GP, Hosseinipour M, Gummadi N.

PLoS One. 2011;6(12):e28691. doi: 10.1371/journal.pone.0028691. Epub 2011 Dec 29. Review.

44.

Multidrug resistant tuberculous meningitis in the United States, 1993-2005.

Vinnard C, Winston CA, Wileyto EP, MacGregor RR, Bisson GP.

J Infect. 2011 Sep;63(3):240-2. doi: 10.1016/j.jinf.2011.07.005. Epub 2011 Jul 19. No abstract available.

PMID:
21784099
45.

Early mortality and AIDS progression despite high initial antiretroviral therapy adherence and virologic suppression in Botswana.

Steele KT, Steenhoff AP, Newcomb CW, Rantleru T, Nthobatsang R, Lesetedi G, Bellamy SL, Nachega JB, Gross R, Bisson GP.

PLoS One. 2011;6(6):e20010. doi: 10.1371/journal.pone.0020010. Epub 2011 Jun 15.

46.

Isoniazid-resistant tuberculous meningitis, United States, 1993-2005.

Vinnard C, Winston CA, Wileyto EP, MacGregor RR, Bisson GP.

Emerg Infect Dis. 2011 Mar;17(3):539-42. doi: 10.3201/eid1703.101715.

47.

Dose-dependent activity of pyrazinamide in animal models of intracellular and extracellular tuberculosis infections.

Ahmad Z, Fraig MM, Bisson GP, Nuermberger EL, Grosset JH, Karakousis PC.

Antimicrob Agents Chemother. 2011 Apr;55(4):1527-32. doi: 10.1128/AAC.01524-10. Epub 2011 Jan 31.

48.

A simple novel method for determining mortality rates in HIV treatment programs worldwide.

Bisson GP.

PLoS Med. 2011 Jan 18;8(1):e1000392. doi: 10.1371/journal.pmed.1000392.

49.

Isoniazid resistance and death in patients with tuberculous meningitis: retrospective cohort study.

Vinnard C, Winston CA, Wileyto EP, Macgregor RR, Bisson GP.

BMJ. 2010 Sep 6;341:c4451. doi: 10.1136/bmj.c4451.

50.

In-hospital mortality of HIV-infected cryptococcal meningitis patients with C. gattii and C. neoformans infection in Gaborone, Botswana.

Steele KT, Thakur R, Nthobatsang R, Steenhoff AP, Bisson GP.

Med Mycol. 2010 Dec;48(8):1112-5. doi: 10.3109/13693781003774689. Epub 2010 May 3.

PMID:
20438294

Supplemental Content

Loading ...
Support Center